Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial

BACKGROUND AND AIMS: Cardiovascular outcome trials have documented a strong benefit of sodium glucose cotransporter-2 inhibitors (SGLT2i) on the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D) with or without established cardiovascular disease or prior history o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonora, Benedetta Maria, Vigili de Kreutzenberg, Saula, Avogaro, Angelo, Fadini, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694690/
https://www.ncbi.nlm.nih.gov/pubmed/31412874
http://dx.doi.org/10.1186/s12933-019-0910-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694690/
https://www.ncbi.nlm.nih.gov/pubmed/31412874
http://dx.doi.org/10.1186/s12933-019-0910-5

Ejemplares similares